Cargando…

The Modified Glasgow Prognostic Scores as a Predictor in Diffuse Large B Cell Lymphoma Treated with R-CHOP Regimen

PURPOSE: The modified Glasgow Prognostic Score (mGPS) consisting of serum C-reactive protein and albumin levels, shows significant prognostic value in several types of tumors. We evaluated the prognostic significance of mGPS in 285 patients with diffuse large B cell lymphoma (DLBCL), retrospectively...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Yundeok, Kim, Soo Jeong, Hwang, Dohyu, Jang, Jieun, Hyun, Shin-Young, Kim, Yu Ri, Kim, Jin Seok, Min, Yoo Hong, Cheong, June-Won
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Yonsei University College of Medicine 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4205696/ https://www.ncbi.nlm.nih.gov/pubmed/25323893 http://dx.doi.org/10.3349/ymj.2014.55.6.1568

Ejemplares similares

Karyotypic change between diagnosis and relapse as a predictor of salvage therapy outcome in AML patients
por: Kim, Yundeok, et al.
Publicado: (2013)

Serum microRNA-21 as a Potential Biomarker for Response to Hypomethylating Agents in Myelodysplastic Syndromes
por: Kim, Yundeok, et al.
Publicado: (2014)

R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma
por: Lee, Hong Ghi, et al.
Publicado: (2014)

Pretreatment Epstein-Barr virus DNA in whole blood is a prognostic marker in peripheral T-cell lymphoma
por: Kim, Yu Ri, et al.
Publicado: (2017)

Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma
por: Jang, Geundoo, et al.
Publicado: (2011)

Different roles of surveillance positron emission tomography according to the histologic subtype of non-Hodgkin’s lymphoma
por: Kim, Yu Ri, et al.
Publicado: (2021)

Clinical significance of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) in acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
por: Kim, Jin Seok, et al.
Publicado: (2011)

Prediction of survival by applying current prognostic models in diffuse large B-cell lymphoma treated with R-CHOP followed by autologous transplantation
por: Lee, Hong Ghi, et al.
Publicado: (2015)

Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia
por: Park, Hyunsung, et al.
Publicado: (2017)

PB2348: OUTCOME OF VERY ELDERLY DIFFUSE LARGE B CELL LYMPHOMA, SINGLE CENTER EXPERIENCE, RETROSPECTIVE ANALYSIS
por: Kong, Jee Hyun, et al.
Publicado: (2023)

Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)
por: Kim, Yu Ri, et al.
Publicado: (2012)

Outcome of R-CHOP or CHOP Regimen for Germinal Center and Nongerminal Center Subtypes of Diffuse Large B-Cell Lymphoma of Chinese Patients
por: Huang, Ying, et al.
Publicado: (2012)

Prognostic significance of BLK expression in R-CHOP treated diffuse large B-cell lymphoma
por: Choi, Soyeon, et al.
Publicado: (2022)

Pretreatment Lymphopenia, Poor Performance Status, and Early Courses of Therapy Are Risk Factors for Severe Bacterial Infection in Patients with Multiple Myeloma during Treatment with Bortezomib-based Regimens
por: Hyun, Shin Young, et al.
Publicado: (2016)

A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas
por: Kim, Jeong Eun, et al.
Publicado: (2012)

Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma
por: Yoo, Changhoon, et al.
Publicado: (2010)

Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma
por: Zhang, Qunling, et al.
Publicado: (2016)

Severe Pulmonary Adverse Effects in Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Regimen Plus Rituximab
por: Lim, Kyu-Hyoung, et al.
Publicado: (2010)

Additional rituximab-CHOP (R-CHOP) versus involved-field radiotherapy after a brief course of R-CHOP in limited, non-bulky diffuse large B-cell lymphoma: a retrospective analysis
por: Hong, Junshik, et al.
Publicado: (2010)

Cyclosporine, prednisone, and high-dose immunoglobulin treatment of angioimmunoblastic T-cell lymphoma refractory to prior CHOP or CHOP-like regimen
por: Chen, Xing-Gui, et al.
Publicado: (2011)

Clinical Response to CHOP vs. R-CHOP in Adult Patients with Diffuse Large B-Cell Lymphomas
por: Tariq, Ayesha, et al.
Publicado: (2018)

The serum CXCL13 level is associated with the Glasgow Prognostic Score in extranodal NK/T-cell lymphoma patients
por: Kim, Seok Jin, et al.
Publicado: (2015)

Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma
por: Fu, Zhiying, et al.
Publicado: (2014)

Aurora A kinase expression is increased in leukemia stem cells, and a selective Aurora A kinase inhibitor enhances Ara-C-induced apoptosis in acute myeloid leukemia stem cells
por: Kim, Soo-Jeong, et al.
Publicado: (2012)

Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP
por: Cho, Kyoung Min, et al.
Publicado: (2019)

Erratum to: The serum CXCL13 level is associated with the Glasgow Prognostic Score in extranodal NK/T-cell lymphoma patients
por: Kim, Seok Jin, et al.
Publicado: (2015)

Enhanced autophagy in cytarabine arabinoside-resistant U937 leukemia cells and its potential as a target for overcoming resistance
por: CHEONG, JUNE-WON, et al.
Publicado: (2016)

A Case of Cutaneous T Cell Lymphoma Masquerading as Keloidal Blastomycosis Treated with CHOP Regimen
por: Reddy, Duttala Indira, et al.
Publicado: (2022)

Clinical Analysis of the HBV Infection Status of 135 Patients with Diffuse Large B Cell Lymphoma Treated with R-CHOP or CHOP/CHOP-Like Chemotherapy
por: Guo, Wei, et al.
Publicado: (2015)

Successful treatment of diffuse large B-cell lymphoma with secondary hemophagocytic lymphohistiocytosis by R-CHOP-E regimen: a case report
por: Wu, Ran, et al.
Publicado: (2019)

Treatment results of radiotherapy following CHOP or R-CHOP in limited-stage head-and-neck diffuse large B-cell lymphoma: a single institutional experience
por: Jeong, Jae-Uk, et al.
Publicado: (2017)

Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab–CHOP
por: Hong, Jung Yong, et al.
Publicado: (2017)

Granisetron plus aprepitant versus granisetron in preventing nausea and vomiting during CHOP or R-CHOP regimen in malignant lymphoma: a retrospective study
por: Wakasugi, Yoshinori, et al.
Publicado: (2019)

Prognostic Nomogram and Predictive Factors in Refractory or Relapsed Diffuse Large B-Cell Lymphoma Patients Failing Front-Line R-CHOP Regimens
por: Jiang, Shiyu, et al.
Publicado: (2020)

Clinical Significance of Non-neutropenic Fever in the Management of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Comparison with Febrile Neutropenia and Risk Factor Analysis
por: Park, Silvia, et al.
Publicado: (2015)

Myeloperoxidase Expression in Acute Myeloid Leukemia Helps Identifying Patients to Benefit from Transplant
por: Kim, Yundeok, et al.
Publicado: (2012)

Clinical characteristics and treatment outcomes of isolated myeloid sarcoma without bone marrow involvement: a single-institution experience
por: Lee, Jung Yeon, et al.
Publicado: (2017)

Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma
por: Terada, Yoshiki, et al.
Publicado: (2009)

P1186: RETROSPECTIVE STUDY: ZANUBRUTINIB COMBINED WITH R-CHOP OR R-CHOP REGIMEN IN THE TREATMENT OF UNTREATED NON-GERMINAL CENTER B-CELL SUBTYPE DIFFUSE LARGE B-CELL LYMPHOMA WITH EXTRANODAL INVOLVEMENT.
por: Caixia, LI, et al.
Publicado: (2023)

Predictive Factors of Event-Free Survival at 24 Months in Patients with Peripheral T-Cell Lymphoma: A Retrospective Study
por: Kim, Yu Ri, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cfl87tvufma2kpknqj8n2sbgdj